These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24387284)

  • 1. The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
    Staudacher AH; Al-Ejeh F; Fraser CK; Darby JM; Roder DM; Ruszkiewicz A; Manavis J; Brown MP
    EJNMMI Res; 2014 Jan; 4(1):2. PubMed ID: 24387284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
    Al-Ejeh F; Darby JM; Brown MP
    PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
    Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
    PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
    Al-Ejeh F; Staudacher AH; Smyth DR; Darby JM; Denoyer D; Tsopelas C; Hicks RJ; Brown MP
    J Nucl Med; 2014 May; 55(5):772-9. PubMed ID: 24676755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.
    Staudacher AH; Bezak E; Borysenko A; Brown MP
    Nucl Med Commun; 2014 Dec; 35(12):1284-90. PubMed ID: 25192189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
    Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
    Liapis V; Tieu W; Wittwer NL; Gargett T; Evdokiou A; Takhar P; Rudd SE; Donnelly PS; Brown MP; Staudacher AH
    Mol Imaging Biol; 2021 Dec; 23(6):914-928. PubMed ID: 34231102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
    Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
    Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody.
    Staudacher AH; Liapis V; Tieu W; Wittwer NL; Brown MP
    J Control Release; 2020 Nov; 327():779-787. PubMed ID: 32946876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
    Mortensen AC; Spiegelberg D; Haylock AK; Lundqvist H; Nestor M
    Int J Oncol; 2018 Jun; 52(6):1875-1885. PubMed ID: 29658563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.
    Staudacher AH; Liapis V; Wittwer NL; Tieu W; Lam HC; Leusen J; Brown MP
    Biomed Pharmacother; 2022 Jul; 151():113090. PubMed ID: 35567988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
    Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
    BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 15. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
    Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
    Al-Ejeh F; Darby JM; Brown MP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5509s-5518s. PubMed ID: 17875783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
    Meredith RF; Alvarez RD; Partridge EE; Khazaeli MB; Lin CY; Macey DJ; Austin JM; Kilgore LC; Grizzle WE; Schlom J; LoBuglio AF
    Cancer Biother Radiopharm; 2001 Aug; 16(4):305-15. PubMed ID: 11603001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.